98%
921
2 minutes
20
Purpose: This study aimed to develop a nomogram combining clinical, sonographic, and radiomic features to discriminate invasive breast cancer (IBC) from noninvasive breast cancer (non-IBC), and to evaluate the prognostic potential of conventional ultrasound (CUS)-based radiomic signatures in predicting breast cancer invasiveness.
Methods: A total of 403 IBCs and 221 non-IBCs were retrospectively collected from multiple institutes. The cases were divided into three subsets based on their institutional origin: a training set (n = 353), an internal test set (n = 153), and an external test set (n = 118). A total of 1125 radiomic features were extracted from the training set of CUS images, and Radiomics Scores (Rad-scores) were constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm. Different nomogram models were constructed using logistic regression, including a clinical-radiomics model (Clinic + Rad), a CUS-clinical model (CUS + Clinic), and a combined CUS-clinical-radiomics model (CUS + Clinic + Rad). The diagnostic performances of these different models were assessed and compared by calculating the area under the receiver operating curve (AUC) as well as the corresponding sensitivity and specificity from the internal and external test sets.
Results: Significant differences were observed between non-IBC and IBC groups in the following variables: Rad-score, age, axillary lymph node metastasis (ALNM), speculated margin, and blood flow (all P < 0.05). On the basis of these factors, the CUS + Clinic + Rad model significantly outperformed other models, with AUC values of 0.91 in the training set, 0.94 in the internal test set, and 0.90 in the external test set(all P < 0.05). Furthermore, the combined model demonstrated significantly higher sensitivity compared to the single Rad-score model (91.7% vs. 80.0%, P < 0.05), while no significant difference was observed in specificity (83.7% vs. 79.6%, P > 0.05). The proposed combined nomogram demonstrated excellent calibration and clinical utility.
Conclusions: Radiomic features significantly enhanced radiologists' diagnostic accuracy in distinguishing non-IBC from IBC. The combined CUS-clinical-radiomics model showed robust performance in predicting invasive status of breast cancer, highlighting its potential for clinical translation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211323 | PMC |
http://dx.doi.org/10.1186/s40001-025-02828-5 | DOI Listing |
JCO Glob Oncol
May 2025
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Breast cancer remains a significant public health challenge globally, as well as in India, where it is the most frequently diagnosed cancer in females. Significant disparities in incidence, mortality, and access to health care across India's sociodemographically diverse population highlight the need for increased awareness, policy reform, and research.
Design: This review consolidates data from national cancer registries, global cancer databases, and institutional findings from a tertiary care center to examine the epidemiology, clinical challenges, and management gaps specific to India.
J Med Screen
September 2025
The Cancer Registry of Norway, Department of Screening programs, Norwegian Institute of Public Health, Oslo, Norway.
ObjectiveTo study the implications of implementing artificial intelligence (AI) as a decision support tool in the Norwegian breast cancer screening program concerning cost-effectiveness and time savings for radiologists.MethodsIn a decision tree model using recent data from AI vendors and the Cancer Registry of Norway, and assuming equal effectiveness of radiologists plus AI compared to standard practice, we simulated costs, effects and radiologist person-years over the next 20 years under different scenarios: 1) Assuming a €1 additional running cost of AI instead of the €3 assumed in the base case, 2) varying the AI-score thresholds for single vs. double readings, 3) varying the consensus and recall rates, and 4) reductions in the interval cancer rate compared to standard practice.
View Article and Find Full Text PDFJ Natl Cancer Inst
September 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States.
Background: Among childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes (AD CSGs) could increase subsequent neoplasm (SNs) risks, but risks for rarer SNs and by age at onset are not well understood.
Methods: We pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years, range 7.
PLoS One
September 2025
Institute of Computational Science and Technology, Guangzhou University, Guangzhou, China.
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology, yet their spatial dynamics within tumor microenvironments (TMEs) remain underexplored due to technical limitations in current spatial transcriptomics (ST) technologies. To address this gap, we present STmiR, a novel XGBoost-based framework for spatially resolved miRNA activity prediction. STmiR integrates bulk RNA-seq data (TCGA and CCLE) with spatial transcriptomics profiles to model nonlinear miRNA-mRNA interactions, achieving high predictive accuracy (Spearman's ρ > 0.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Objective: This study employs integrated network toxicology and molecular docking to investigate the molecular basis underlying 4-nonylphenol (4-NP)-mediated enhancement of breast cancer susceptibility.
Methods: We integrated data from multiple databases, including ChEMBL, STITCH, Swiss Target Prediction, GeneCards, OMIM and TTD. Core compound-disease-associated target genes were identified through Protein-Protein Interaction (PPI) network analysis.